查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球多发性骨髓瘤市场
市场调查报告书
商品编码
1292935

2023-2030年全球多发性骨髓瘤市场

Global Multiple Myeloma Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 170 Pages | 商品交期: 2-3个工作天内

价格

在预测期内，全球多发性骨髓瘤市场预计将以4.8%的可观复合增长率增长。该市场的增长归因于多发性骨髓瘤发病率的增加以及诊断和治疗技术的进步等因素。例如，根据加利福尼亚大学的数据，2020年，全球有近176,404个或95%的多发性骨髓瘤新病例被报告。此外，根据加拿大癌症协会的数据，2022年新诊断的骨髓瘤病例为4000例，其中男性2400例，女性1550例，每天有近11人被诊断患有骨髓瘤。然而，由于新开发的靶向治疗和移植技术的引入，多发性骨髓瘤的发病率得到降低。例如，2023年2月，纪念斯隆-凯特琳癌症中心（MSK）的研究人员公布了一项临床试验的结果，发现复发性多发性骨髓瘤患者在病程的早期接受嵌合抗原受体（CAR）T疗法，会得到好处。通过这种疗法，完全缓解率提高了近7倍，而且治疗后体内没有发现癌症。

分段展望：

全球多发性骨髓瘤市场根据其药物类别、类型和分销渠道进行细分。根据药物类别，市场被细分为免疫调节剂、蛋白酶体抑制剂、抗CD38单克隆抗体、烷化剂和其他。根据其类型，市场被分为超二倍体（HMM）和非超二倍体或超二倍体。此外，根据分销渠道，市场被划分为医院药房、零售药房和药店以及网上药店。在分销渠道中，由于医院有训练有素的医务人员，为病人提供更好的服务，加上医院收治病人的增加，预计医院子板块将表现出最高的增长。

高二倍体(HMM)细分市场预计将在全球多发性骨髓瘤市场占据主要市场份额

目录

  • Aurobindo制药公司
  • Aurobindo Pharma Ltd.
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche有限公司
  • 费森尤斯卡比公司
  • Genentech, Inc.
  • Hikma Pharmaceuticals PLC
  • Karyopharm Therapeutics Inc.
  • Oncopeptides AB
  • 小野制药有限公司
  • Sanofi S.A.
  • 太阳制药工业有限公司
  • 武田药品美国公司。
  • 梯瓦制药工业有限公司
Product Code: OMR2027318

Global Multiple Myeloma Market Size, Share & Trends Analysis Report by Drug Class (Immunomodulators, Proteasome Inhibitors, Anti-CD38 Monoclonal Antibody, Alkylating Agents, and Others), by Type (Hyperdiploid, and Non-Hyperdiploid or Hypodiploid), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies) Forecast Period (2023-2030)

The global multiple myeloma market is anticipated to grow at a considerable CAGR of 4.8% during the forecast period. The growth of the market is attributed to factors such as the increasing prevalence of multiple myeloma and advancements in diagnostic and treatment technologies. For instance, according to the University of California, in 2020, nearly 176,404 or 95% new cases of multiple myeloma were reported globally. Moreover, according to the Canadian Cancer Society, the number of new myeloma cases diagnosed in 2022 was 4,000, among them 2,400 males and 1,550 females, and nearly 11 people are diagnosed with myeloma each day. However, due to the introduction of newly developed targeted therapies and transplantation techniques, the rate of multiple myeloma get reduced. For instance, in February 2023, investigators at Memorial Sloan Kettering Cancer Center (MSK) published results from a clinical trial that found people with recurrent multiple myeloma get benefited from receiving chimeric antigen receptor (CAR) T therapy earlier in the course of their disease. With this therapy there was a nearly sevenfold increase in complete remission rates, and no cancer was detected in the body after the treatment.

Segmental Outlook

The global multiple myeloma market is segmented based on its drug class, type, and distribution channel. Based on the drug class, the market is sub-segmented into immunomodulators, proteasome inhibitor, anti-CD38 monoclonal antibody, alkylating agents, and others. Based on its type, the market is bifurcated into hyperdiploid (HMM) and non-hyperdiploid or hypodiploid. Further, based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies. Among the distribution channel, the hospital sub-segment is projected to exhibit the highest growth, owing to the availability of trained medical staff in hospitals that provide better services to patients along with an increase in patient admission in hospitals.

Hyperdiploid (HMM) Sub-Segment Expected to Hold a Major Market Share in the Global Multiple Myeloma Market

Among the type segment, the hyperdiploid (HMM) sub-segment is anticipated to register significant growth for the forecast period. The growth of the HMM sub-segment is attributed to factors such as increasing R&D activities and rising demand for personalized medicine. For instance, in 2021, Janssen Biotech, Inc. announced the US FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed or relapsed/refractory multiple myeloma.

Regional Outlooks

The global multiple myeloma market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these, North America is anticipated to grow at a significant CAGR over the forecast period. The growth is attributed to a rise in number of government funding organizations for R&D of cancer and increase in prevalence of multiple myeloma.

Global Multiple Myeloma Market Growth, by Region 2023-2030

Source: OMR Analysis

The North America Region Anticipated to Dominate the Multiple Myeloma Market

The growth of the market in the region is driven by the presence of key players such as Novartis AG, Bristol Myers Squibb, Amgen Inc., AbbVie, and others, coupled with an increase in the number of product launches, and new product approvals for multiple myeloma drugs. For instance, in January 2022, Bristol-Myers Squibb announced that Japan's Ministry of Health, Labor and Welfare approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma. Moreover, in December 2021, Amgen announced that the US Food and Drug Administration (FDA) approved the expansion of the KYPROLIS (carfilzomib) US prescribing information to include its use in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Market Players Outlook

The major companies serving the global multiple myeloma market include: Abbott Laboratories, Amgen Inc., GlaxoSmithKline plc, Merck & Co., Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, AbbVie acquired the TeneoOne and its key immunotherapeutic asset for treating multiple myeloma named TNB-383B. TNB-383B is a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. Through this partnership, both companies aim to develop and commercialize TNB-383B, a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's immune system to target and kill BCMA-expressing tumor cells.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global multiple myeloma market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott Laboratories
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Amgen Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. GlaxoSmithKline plc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Merck & Co., Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Novartis AG
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Multiple Myeloma Market by Drug Class
    • 4.1.1. Immunomodulators
    • 4.1.2. Proteasome Inhibitor
    • 4.1.3. Anit-CD38 Monoclonal Antibody
    • 4.1.4. Alktlating Agents
    • 4.1.5. Others
  • 4.2. Global Multiple Myeloma Market by Type
    • 4.2.1. Hyperdiploid (HMM)
    • 4.2.2. Non-Hyperdiploid or Hypodiploid
  • 4.3. Global Multiple Myeloma Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies & Drug Stores
    • 4.3.3. Online Pharmacies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Aurobindo Pharma
  • 6.2. Aurobindo Pharma Ltd.
  • 6.3. Bristol-Myers Squibb Co.
  • 6.4. Cipla Inc.
  • 6.5. Eli Lilly and Co.
  • 6.6. F. Hoffmann-La Roche Ltd.
  • 6.7. Fresenius Kabi AG
  • 6.8. Genentech, Inc.
  • 6.9. Hikma Pharmaceuticals PLC
  • 6.10. Karyopharm Therapeutics Inc.
  • 6.11. Oncopeptides AB
  • 6.12. Ono Pharmaceutical Co., Ltd.
  • 6.13. Sanofi S.A.
  • 6.14. Sun Pharmaceutical Industries Ltd.
  • 6.15. Takeda Pharmaceuticals U.S.A., Inc.
  • 6.16. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 2. GLOBAL IMMUNOMODULATORS FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PROTEASOME INHIBITOR FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ANTI-CD38 MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL ALKYLATING AGENTS FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHER DRUGS FOR FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 8. GLOBAL HYPERDIPLOID (HMM) MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL NON-HYPERDIPLOID OR HYPODIPLOID MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 11. GLOBAL MULTIPLE MYELOMA IN HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL MULTIPLE MYELOMA IN RETAIL PHARMACIES & DRUG STORES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL MULTIPLE MYELOMA IN ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 19. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 21. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY DRUG CLASS, 2022 VS 2030 (%)
  • 2. GLOBAL IMMUNOMODULATORS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PROTEASOME INHIBITORS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ANTI-CD38 MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL ALKYLATING AGENTS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHER DRUGS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 8. GLOBAL HYPERDIPLOID (HMM) MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL NON-HYPERDIPLOID OR HYPODIPLOID MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 11. GLOBAL MULTIPLE MYELOMA IN HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL MULTIPLE MYELOMA IN RETAIL PHARMACIES & DRUG STORES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL MULTIPLE MYELOMA IN ONLINE PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)